---
id: nccn-crc-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer"
short_title: "Colorectal Cancer"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Colorectal Cancer
  - Colon Cancer
  - Rectal Cancer
tags:
  - colorectal cancer
  - colon cancer
  - rectal cancer
  - immunotherapy
  - chemotherapy
publication_date: 2025-01-15
previous_version_date: 2024-01-20
status: current
supersedes: nccn-crc-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the screening, diagnosis, staging, treatment, and surveillance of colorectal cancer.

## Key Recommendations

### Molecular Testing
- All patients: MMR/MSI testing
- Metastatic: KRAS, NRAS, BRAF, HER2
- Consider NTRK fusion testing

### Stage I Colon Cancer
- Surgical resection with lymph node evaluation
- No adjuvant chemotherapy

### Stage II Colon Cancer
- Surgery ± adjuvant chemotherapy
- Consider adjuvant for high-risk features (T4, LVI, <12 nodes, poorly differentiated)
- MSI-H: Generally no adjuvant chemo (good prognosis)

### Stage III Colon Cancer
- Surgery + adjuvant chemotherapy
- FOLFOX or CAPOX standard (3-6 months based on risk)
- Low-risk T1-3N1: 3 months of CAPOX

### Rectal Cancer
- Total neoadjuvant therapy (TNT) for locally advanced
- Short-course RT or long-course CRT options
- Total mesorectal excision (TME)
- Consider watch-and-wait for clinical complete response (investigational)

### Metastatic CRC - First Line
**MSI-H/dMMR:**
- Pembrolizumab or nivolumab ± ipilimumab (preferred)

**MSS (RAS/BRAF wild-type):**
- FOLFOX/FOLFIRI + anti-EGFR (cetuximab/panitumumab) for left-sided
- FOLFOX/FOLFIRI + bevacizumab

**MSS (RAS mutant):**
- FOLFOX/FOLFIRI + bevacizumab

**BRAF V600E mutant:**
- FOLFOXIRI + bevacizumab, or
- Encorafenib + cetuximab (especially later line)

### Oligometastatic Disease
- Consider resection/ablation of liver or lung metastases
- Multidisciplinary discussion

### Surveillance
- CEA, CT scans, colonoscopy per protocol
